Purchase Order 75N92B25P00229

Award Date 6/16/25
Potential Completion Date 6/15/26
Potential Value $25K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Competed under SAP
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
San Jose, CA 95131, USA
Solicitation Procedures
Simplified Acquisition
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
Takara Bio USA, Inc. was awarded a $24,900.00 firm fixed-price purchase order contract by the National Institutes of Health (NIH) National Institute of Arthritis and Musculoskeletal and Skin Diseases. The contract, which has a completion date of May 31, 2025, does not have a set-aside designation. As a prime contractor, Takara Bio USA, Inc. will provide specialized biomedical products and services to support NIH's research programs, including proprietary kits and reagents for single-cell...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Takara Bio USA, Inc., a prominent provider of specialized biomedical products and services to the U.S. federal government. The contract, valued at $2,508.00, is for the supply of various genomics, cell biology, and molecular diagnostics tools, including products such as SmartScribe Reverse Transcriptase, SeqAmp DNA Polymerase, and RetroNectin GMP Grade Reagent. These products...
This is a $6,327.00 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Takara Bio USA, Inc., a prominent provider of specialized biomedical products and services to the federal government. The contract, which was not set aside for small businesses, is for the delivery of AMBIS # 1743568 KIT, a product that likely supports advanced research in areas such as infectious diseases,...
This is a $25,956.00 firm fixed-price delivery order awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to Takara Bio USA, Inc., a for-profit manufacturer of specialized biomedical products and services. The contract is for the period of February 24, 2016 to July 15, 2016, and does not have a small business set-aside designation. Takara Bio USA, Inc. is a prime contractor providing the National Cancer Institute with research tools...
This is a $11,916.60 firm fixed-price purchase order contract awarded by the National Institutes of Health (NIH) Clinical Center to Takara Bio USA, Inc., a for-profit manufacturer of biomedical products and life sciences research tools. The contract is for the supply of 2.5 ml of RetroNectin GMP grade, a critical reagent used in various cutting-edge scientific research areas supported by NIH, including COVID-19, genomics, cellular therapy, and other disciplines. The contract has no set-aside...
This federal contract award, valued at $16,880.55, was issued by the National Institute on Aging (NIA), a component of the U.S. Department of Health and Human Services, to Takara Bio USA, Inc. The contract is for the procurement of laboratory supplies, specifically the SMART-SEQ mRNA LP (with UMIs) and four unique dual index kits. Takara Bio USA, a for-profit manufacturer of specialized biomedical products, has provided similar reagents and instruments to various NIH institutes and other federal...
This is a firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services, to Takara Bio USA, Inc. The contract, valued at $19,975.65, is for the procurement of SMARTSEQ reagents (AMBIS #2226785) to support the agency's biomedical research activities. Takara Bio USA, a prominent manufacturer of specialized life sciences products, has a long-standing relationship with federal...
The Department of Health and Human Services National Institutes of Health National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $189,000.00 firm fixed-price purchase order to Takara Bio USA, Inc., a manufacturer of biomedical goods and life science reagents, to provide a TAKARA ICELL8 CX SINGLE-CELL SYSTEM PLATFORM. This award was designated as a Total Small Business set-aside. The platform will be used in the NIAMS Genomics Technology Section Core Facility to...
The Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases awarded a firm fixed-price purchase order to Takara Bio USA, Inc. to provide SEQUENCING KITS. The $5,747.50 contract has a completion date of September 28, 2017. Takara Bio USA, Inc. is a for-profit manufacturer of biomedical products and services, including next-generation sequencing and molecular biology tools, that frequently provides specialized products to...
This federal contract award with ID HHSN272201500527P was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to the prime contractor Takara Bio USA, Inc. The $4,730.05 Firm Fixed Price purchase order is for the provision of specialized biomedical products and services in support of life sciences research, such as genomics, cell biology, and molecular diagnostics tools. Takara Bio USA, as a subsidiary of the...

This is a firm fixed-price purchase order contract awarded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a civilian agency within the National Institutes of Health (NIH), to Takara Bio USA, Inc. The contract, valued at $24,900.00, is for the provision of ICELL8 service for a one-year period from June 16, 2025 to June 15, 2026. Takara Bio USA, Inc. is a for-profit manufacturer of biomedical products and life sciences research tools, with a focus on genomics, molecular biology, and cellular technologies. The contract supports critical research areas, including COVID-19 research, genomic sequencing, cellular therapy, and various scientific investigations across environmental, medical, and biological research domains. There is no set-aside designation for this contract.

Generated 6/14/25, 10:47 AM